ISA101b long peptide targets HPV16-positive cervical cancer, receives FDA-awarded orphan drug title

ISA Pharmaceuticals announced its main candidate, ISA101b, for the treatment of 16 type of human papillomavirus (HPV16) positive cervical cancer, and was awarded the title of "orphan drug" by the U.SFood and Drugadministration(
FDA)According to the latest statistics from the Centers for Disease Control andPrevention and, HPV causes more than 34,000 cancers in the United States each yearCervical cancer is the most common HPV-related cancer in women, of which HPV16 accounts for about 50%HPV16-positive cervical cancer is the second largest cancer in 15-44-year-old women in the United StatesThe incidence of cervical cancer is declining at a rate of 1% per year as a result ofscreeningand vaccinationThe SEER database estimates that there will be about 13,800 new cases and 4,290 cervical cancer deaths in the United States by 2020ISA101b is a clinical phase of HPV16-induced cervical cancer and pharynx cancer
immuno therapy, based on ISA's proprietary synthetic peptide technology, induces a specific immune response to HPV16 cancer-causing E6 and E7 proteins The product has successfully and safely completed a number of human clinical studies in more than 200 patients Photo Source: ISA101 has been shown to be effective in patients with early, HPV16-positive, pre-variant tumors is able to work with chemotherapy in advanced HPV16-positive cervical cancer Advanced cancers cause local and systemic immunosuppression due to chemotherapy, such as carpurine and yew alcohol, while ISA101b attacks cancer more effectively by activating T-cell immunity Phase 2 clinical study confirmed that ISA101b and nivolumab (anti-PD1 antibody) were combined with the second-line treatment, with tumor response and total survival rates about twice as high as anti-PD1 monotherapy